NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Overview Fund Activity
Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

35 hedge funds and large institutions have $31.1M invested in NeuBase Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 0 closing their positions.

Holders
35
Holders Change
+21
Holders Change %
+150%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
10
Reduced
3
Closed
–
Calls
$32K
Puts
$93K
Net Calls
-$61K
Net Calls Change
-$61K

Top Buyers

1
Millennium Management
1
Millennium Management
New York
$12.2M
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.6M
3
EI
3
EAM Investors
California
$2.23M
4
U
4
UBS
Switzerland
$935K
5
BIM
5
Bogle Investment Management
Massachusetts
$880K

Top Sellers

1
TRCT
1
Tower Research Capital (TRC)
New York
$4K
2
FNBT
2
FineMark National Bank & Trust
Florida
$54K
3
Goldman Sachs
3
Goldman Sachs
New York
$1.85M
Name Holding Trade Value Shares
Change 		Shares
Change %
Wells Fargo
26
Wells Fargo
California
$96K +$90.7K +17 +1,700%
BIT
27
BlackRock Institutional Trust
California
$80K +$64K +12 +400%
Deutsche Bank
28
Deutsche Bank
Germany
$59K +$37.5K +7 +175%
FNBT
29
FineMark National Bank & Trust
Florida
$54K -$27K -5 -33%
HF
30
Hoxton Financial
West Virginia
$46K +$46K +8 New
HCC
31
Hirtle Callaghan & Co
Pennsylvania
$32K +$32K +6 New
Citigroup
32
Citigroup
New York
$15K +$15K +3 New
Bank of America
33
Bank of America
North Carolina
$14K +$14K +3 New
TC
34
TradeLink Capital
Illinois
$12K +$12K +2 New
TRCT
35
Tower Research Capital (TRC)
New York
$4K -$28K -7 -88%
1
2